Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 0.67 |
| ▸ | ADRB1 | P08588 | 14/20 | 0.67 |
| ▸ | ADRA1D | P25100 | 14/20 | 0.67 |
| ▸ | DRD2 | P14416 | 13/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4718977 | 0.92 | ADRB2 (0.66) | ADRB2ADRB1ADRA1DDRD2 | |
| SCHEMBL4716866 | 0.90 | ADRB2 (0.67) | ADRB2ADRB1ADRA1DDRD2 | |
| SCHEMBL4712118 | 0.88 | ADRB2 (0.63) | ADRB2ADRB1ADRA1DDRD2 | |
| SCHEMBL4557988 | 0.88 | ADRB2 (0.68) | ADRB2ADRB1ADRA1DDRD2 | |
| Hydrochloric Acid SCHEMBL4790456 | 0.87 | ADRB2 (0.62) | ADRB2ADRB1ADRA1DDRD2 | |
| SCHEMBL4712722 | 0.87 | ADRB2 (0.77) | ADRB2ADRB1ADRA1DDRD2 | |
| Hydrochloric Acid SCHEMBL4715380 | 0.87 | ADRB2 (0.67) | ADRB2ADRB1ADRA1DDRD2 | |
| SCHEMBL4714962 | 0.86 | ADRB2 (0.64) | ADRB2ADRB1ADRA1DDRD2 | |
| SCHEMBL1801008 | 0.86 | ADRB2 (0.72) | ADRB2ADRB1ADRA1DDRD2 | |
| SCHEMBL4719695 | 0.85 | ADRB2 (0.67) | ADRB2ADRB1ADRA1DDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996566-A1 | BEZOTHIAZOL DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | AstraZeneca AB (SE) | 2008-12-03 | — | — | EP | claimed |
| WO-2007106016-A1 | BEZOTHIAZOL DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | WO | claimed |